Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/11/26
Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to SayZacks Investment Research • 03/02/26
Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass EstimatesZacks Investment Research • 03/02/26
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 GuidanceBusiness Wire • 03/02/26
Unlocking Q4 Potential of Xeris Biopharma (XERS): Exploring Wall Street Estimates for Key MetricsZacks Investment Research • 02/26/26
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026Business Wire • 02/17/26
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total RevenueBusiness Wire • 01/08/26
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business Wire • 01/02/26
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent ApplicationBusiness Wire • 12/01/25
Xeris Biopharma (XERS) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research • 11/06/25
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025Business Wire • 10/23/25
Are You Looking for a Top Momentum Pick? Why Xeris Biopharma (XERS) is a Great ChoiceZacks Investment Research • 10/20/25
Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue?Zacks Investment Research • 10/20/25
Xeris Biopharma (XERS) Surges 14.2%: Is This an Indication of Further Gains?Zacks Investment Research • 10/16/25
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 10/03/25
Xeris Biopharma (XERS) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 10/03/25
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?Zacks Investment Research • 10/03/25